Clinical perspective of the COAST-study for unresectable Stage III NSCLC
In this MEDtalk Roy S. Herbst, Medical Oncologist answers questions about the COAST-study of patients with locally advanced, unresectable, stage III NSCLC with durmavumab alone or in combination with novel agents.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
